These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36758520)

  • 21. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
    Ukena SN; Singh A; Dringenberg U; Engelhardt R; Seidler U; Hansen W; Bleich A; Bruder D; Franzke A; Rogler G; Suerbaum S; Buer J; Gunzer F; Westendorf AM
    PLoS One; 2007 Dec; 2(12):e1308. PubMed ID: 18074031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation.
    Whelan RA; Rausch S; Ebner F; Günzel D; Richter JF; Hering NA; Schulzke JD; Kühl AA; Keles A; Janczyk P; Nöckler K; Wieler LH; Hartmann S
    Mol Ther; 2014 Oct; 22(10):1730-40. PubMed ID: 24985163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects resulting from oral administration of
    Souza ELS; Campos CLV; Reis DC; Cassali GD; Generoso SV; Cardoso VN; Azevedo V; Medeiros JD; Fernandes GR; Nicoli JR; Martins FS
    Benef Microbes; 2020 Dec; 11(8):779-790. PubMed ID: 33191778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.
    Schultz M
    Inflamm Bowel Dis; 2008 Jul; 14(7):1012-8. PubMed ID: 18240278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protocol for engineering E. coli Nissle 1917 to diagnose, record, and ameliorate inflammatory bowel disease in mice.
    Zou ZP; Fan YH; Du Y; Fang TT; Du W; Zhou Y; Ye BC
    STAR Protoc; 2023 Apr; 4(2):102254. PubMed ID: 37115666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutritional Support and Probiotics as a Potential Treatment of IBD.
    Tarasiuk A; Eibl G
    Curr Drug Targets; 2020; 21(14):1417-1427. PubMed ID: 32364071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probiotics alleviate inflammatory bowel disease in mice by regulating intestinal microorganisms-bile acid-NLRP3 inflammasome pathway.
    Liu Z; Wang H
    Acta Biochim Pol; 2021 Oct; 68(4):687-693. PubMed ID: 34648252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.
    Eindor-Abarbanel A; Healey GR; Jacobson K
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probiotics and inflammatory bowel disease.
    Kwon J; Farrell R
    BioDrugs; 2003; 17(3):179-86. PubMed ID: 12749754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestinal Engineered Probiotics as Living Therapeutics: Chassis Selection, Colonization Enhancement, Gene Circuit Design, and Biocontainment.
    Huang Y; Lin X; Yu S; Chen R; Chen W
    ACS Synth Biol; 2022 Oct; 11(10):3134-3153. PubMed ID: 36094344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.
    Zhou J; Li M; Chen Q; Li X; Chen L; Dong Z; Zhu W; Yang Y; Liu Z; Chen Q
    Nat Commun; 2022 Jun; 13(1):3432. PubMed ID: 35701435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synbiotic supplementation with prebiotic green banana resistant starch and probiotic Bacillus coagulans spores ameliorates gut inflammation in mouse model of inflammatory bowel diseases.
    Shinde T; Perera AP; Vemuri R; Gondalia SV; Beale DJ; Karpe AV; Shastri S; Basheer W; Southam B; Eri R; Stanley R
    Eur J Nutr; 2020 Dec; 59(8):3669-3689. PubMed ID: 32067099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment.
    Coqueiro AY; Raizel R; Bonvini A; Tirapegui J; Rogero MM
    Int J Food Sci Nutr; 2019 Feb; 70(1):20-29. PubMed ID: 29804478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exopolysaccharide-producing probiotic strains on experimental colitis in rats.
    Sengül N; Aslím B; Uçar G; Yücel N; Işik S; Bozkurt H; Sakaoğullari Z; Atalay F
    Dis Colon Rectum; 2006 Feb; 49(2):250-8. PubMed ID: 16362802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-Generation Probiotics for Inflammatory Bowel Disease.
    Pesce M; Seguella L; Del Re A; Lu J; Palenca I; Corpetti C; Rurgo S; Sanseverino W; Sarnelli G; Esposito G
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of
    Zhang F; Li Y; Wang X; Wang S; Bi D
    Biomed Res Int; 2019; 2019():3921315. PubMed ID: 30915354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease?
    Satta R; Pes GM; Rocchi C; Pes MC; Dore MP
    J Dermatolog Treat; 2019 Sep; 30(6):612-616. PubMed ID: 30244616
    [No Abstract]   [Full Text] [Related]  

  • 38. Isolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probiotics.
    Celiberto LS; Pinto RA; Rossi EA; Vallance BA; Cavallini DCU
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic Lactobacillus reuteri.
    Gao C; Major A; Rendon D; Lugo M; Jackson V; Shi Z; Mori-Akiyama Y; Versalovic J
    mBio; 2015 Dec; 6(6):e01358-15. PubMed ID: 26670383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis.
    Philippe D; Heupel E; Blum-Sperisen S; Riedel CU
    Int J Food Microbiol; 2011 Sep; 149(1):45-9. PubMed ID: 21257218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.